Myocarditis Following SARS-CoV2 mRNA Vaccination Against COVID-19

[1]  Sarah E. Wilson,et al.  Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada , 2022, JAMA network open.

[2]  Carl A. B. Pearson,et al.  Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis , 2022, The Lancet Regional Health - Europe.

[3]  H. Sørensen,et al.  SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study , 2021, BMJ.

[4]  R. Balicer,et al.  Myocarditis after Covid-19 Vaccination in a Large Health Care Organization , 2021, The New England journal of medicine.

[5]  Manfred S. Green,et al.  Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel , 2021, The New England journal of medicine.

[6]  P. Ponikowski,et al.  COVID‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology , 2021, European journal of heart failure.

[7]  Rosalind J Wright,et al.  Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine , 2021, Cell.

[8]  D. Mann,et al.  Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017 , 2021, Frontiers in Cardiovascular Medicine.

[9]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[10]  T. Kuno,et al.  Myocardial injury characterized by elevated cardiac troponin and in‐hospital mortality of COVID‐19: An insight from a meta‐analysis , 2020, Journal of medical virology.